Sunny Pharmtech

Sunny Pharmtech OCF Margin

The Operating Cash Flow Margin of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -8.87 %. In the previous year, Operating Cash Flow Margin was 8.89 % — a change of -199.88% (lower).

OCF Margin

-8.87 %

YoY

-199.88%

Last updated:

Operating Cash Flow Margin of Sunny Pharmtech is 2024 -8.87 % . Operating Cash Flow Margin of Sunny Pharmtech was 2023 8.89 % . It decreases by -199.88% lower compared to the previous year.

The Sunny Pharmtech OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-213.97 TWD
Jan 1, 2019
-50.27 TWD
Jan 1, 2020
-6.20 TWD
Jan 1, 2021
-14.25 TWD
Jan 1, 2022
7.48 TWD
Jan 1, 2023
8.89 TWD
Jan 1, 2024
-8.87 TWD
The Sunny Pharmtech OCF Margin history
YEAROCF MarginYoY
-8.87 %-199.88%
8.89 %+18.87%
7.48 %-152.44%
-14.25 %+129.85%
-6.20 %-87.66%
-50.27 %-76.51%
-213.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

Operating Cash Flow Margin of Sunny Pharmtech is -8.87 % in 2024.

Operating Cash Flow Margin of Sunny Pharmtech changed from 8.89 % to -8.87 %, representing a -199.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech